ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 906,14
-0,26%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XOMA Corporation (XOMAP)

  7. XOMA Corporation (XOMAP) Actualités

XOMAP XOMA Corporation

25,02
-0,2599 (-1,03%)
17 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
XOMA Corporation XOMAP NASDAQ Action préférentielle
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,2599 -1,03% 25,02 22:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
25,28 25,02 25,28 25,02 25,28
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202413:31EDGAR2Form 8-K - Current report
14/5/202413:30GLOBEXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect..
09/5/202413:45EDGAR2Form 8-K - Current report
09/5/202413:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:30GLOBEXOMA Reports First Quarter 2024 Financial Results and..
30/4/202413:30GLOBEXOMA Adds Economic Interests in Three First-in-Category..
25/4/202413:30GLOBEXOMA Earns $9 Million Milestone as FDA Grants Accelerated..
03/4/202415:00GLOBEXOMA Corporation Announces Closing of Tender Offer
21/3/202412:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
19/3/202421:05GLOBEXOMA Announces Calculation of Additional Price Per Share and..
11/3/202411:56EDGAR2Form S-4 - Registration of securities, business combinations
08/3/202422:34EDGAR2Form S-3 - Registration statement under Securities Act of..
08/3/202413:39EDGAR2Form 8-K - Current report
08/3/202413:30GLOBEXOMA Reports Fourth Quarter and Full Year 2023 Financial..
04/3/202423:24EDGAR2Form SC TO-T - Tender offer statement by Third Party
28/2/202413:30GLOBEXOMA to Present at Upcoming Investor Conferences in March
16/2/202415:08EDGAR2Form 8-K - Current report
16/2/202414:00GLOBEXOMA Enters into Agreement to Acquire Kinnate Biopharma for..
18/1/202414:30GLOBEXOMA Expands its Commercial Royalty and Milestone Portfolio..
16/1/202423:22EDGAR2Form SC 13D/A - General statement of acquisition of..
11/1/202422:31EDGAR2Form 8-K - Current report
11/1/202422:05GLOBEFDA Acceptance of Zevra’s Arimoclomol NDA Filing for..
10/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:30GLOBEXOMA Names Owen Hughes as Chief Executive Officer and..
02/1/202413:46EDGAR2Form 8-K - Current report
02/1/202413:30GLOBEXOMA Announces Stock Repurchase Program of up to $50 Million
20/12/202313:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
19/12/202313:40EDGAR2Form 8-K - Current report
19/12/202313:30GLOBEXOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse..
07/11/202313:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:40EDGAR2Form 8-K - Current report
07/11/202313:30GLOBEXOMA Reports Third Quarter 2023 Financial Results and..
31/10/202312:35EDGAR2Form 8-K - Current report
31/10/202312:30GLOBEXOMA Earns $5 Million Milestone Upon FDA Acceptance of Day..
27/10/202323:06EDGAR2Form 8-K - Current report
04/10/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202313:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
11/9/202322:10EDGAR2Form 8-K - Current report
06/9/202313:30GLOBEXOMA to Present at H.C. Wainwright 25th Annual Global..
25/8/202323:09EDGAR2Form 8-K - Current report
08/8/202313:41EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:35EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
XOMAP
XOMA
BIT
UIG466
Unicredit Bank
BOV
AFHI11
AF Invest CRI Fundo DE I...
TSXV
EGT
Eguana Technologies
LSE
0DM3
Artprice Com
COIN
SLNDUST
Solend
LSE
0A7Y
Wabtec
LSE
0JJ4
Ishares Global Materials...
EU
J327S
J327S
LSE
BWRA
Bristol Wtr.8t%
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés